Latest / DDReg Knowledge Capsule / Malaysia NPRA 2026: Fast Route for Biosimilar Registration

Transcript

Malaysia NPRA 2026: Fast Route for Biosimilar Registration · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to D.D. Reg Knowledge Capsule. Imagine inventing a life-saving drug.
• 0:05
  Speaker 1: I mean, proving to the world's strictest scientists that it
• 0:09
  Speaker 1: works flawlessly.
• 0:10
  Speaker 2: Right. And then being told you have to wait three
• 0:12
  Speaker 2: years just to fill out the paperwork to sell it
• 0:14
  Speaker 2: in another country.
• 0:15
  Speaker 1: Exactly. Historically, that has been the grueling reality of global
• 0:20
  Speaker 1: pharmaceutical launches.
• 0:21
  Speaker 2: It really has.
• 0:22
  Speaker 1: You spend billions navigating the U.S. FDA line. Then you
• 0:25
  Speaker 1: get out of that line, take a breath, and, you know...
• 0:28
  Speaker 1: go stand at the very back of a completely different
• 0:31
  Speaker 1: line for Europe.
• 0:32
  Speaker 2: Yeah. And then maybe a year later, you start a
• 0:34
  Speaker 2: new line for Asia.
• 0:35
  Speaker 1: It's a slow, sequential march.
• 0:37
  Speaker 2: Yeah.
• 0:37
  Speaker 1: And it costs developers millions in potential revenue. But more importantly,
• 0:42
  Speaker 1: it delays patient access to critical treatments.
• 0:46
  Speaker 2: The historical burden of all these redundant scientific reviews, I mean,
• 0:49
  Speaker 2: it cannot be overstated.
• 0:50
  Speaker 1: Right.
• 0:51
  Speaker 2: Every single sovereign nation has the right and honestly the
• 0:54
  Speaker 2: responsibility to protect its own citizens.
• 0:56
  Speaker 1: Of course.
• 0:57
  Speaker 2: So for decades, that meant every national health authority demanded
• 1:00
  Speaker 2: their own ground-up review of a drug's data, regardless of
• 1:04
  Speaker 2: who else had already approved it.
• 1:06
  Speaker 1: Which created a massive global backlog.
• 1:08
  Speaker 2: A huge one. But what we are seeing now is
• 1:11
  Speaker 2: a fundamental shift in how countries trust each other's science.
• 1:15
  Speaker 1: Today, we are diving into a major example of that shift.
• 1:18
  Speaker 1: We are looking at Malaysia's National Pharmaceutical Regulatory Agency, or NPRA,
• 1:23
  Speaker 1: and their brand new 2026 fast route for biosimilar registration.
• 1:28
  Speaker 2: It's a really big deal.
• 1:30
  Speaker 1: Our insights today come directly from Detroit Pharma. And our
• 1:32
  Speaker 1: mission for this deep dive is to look past the
• 1:34
  Speaker 1: flashy headlines of this new 60 working day regulatory timeline.
• 1:39
  Speaker 2: Because there's a lot hiding behind that number.
• 1:41
  Speaker 1: There really is. We are going to explore what a
• 1:43
  Speaker 1: reliance pathway actually is, the incredibly strict fine print required
• 1:48
  Speaker 1: to get your application accepted, and how this is forcing
• 1:51
  Speaker 1: pharmaceutical companies to completely tear up and rewrite their global
• 1:54
  Speaker 1: launch strategies.
• 1:55
  Speaker 2: The stakes here are incredibly high. For a regulatory strategy
• 1:59
  Speaker 2: leader securing an early approval in a key Southeast Asian
• 2:02
  Speaker 2: market like Malaysia, well, it changes the entire financial calculus
• 2:06
  Speaker 2: of a drug launch. Yeah.
• 2:07
  Speaker 1: Whether you're prepping for a global regulatory strategy meeting, or
• 2:11
  Speaker 1: you're just curious about how global health systems approve complex medicines,
• 2:16
  Speaker 1: this deep dive is going to break down this shift
• 2:19
  Speaker 1: without the overwhelm.
• 2:20
  Speaker 2: Because the surface level headline is definitely hiding a gauntlet
• 2:24
  Speaker 2: of technical requirements.
• 2:25
  Speaker 1: Okay, let's unpack this. We have to start with that
• 2:27
  Speaker 1: headline number, you know, 60 working days.
• 2:30
  Speaker 2: Right.
• 2:30
  Speaker 1: Under Malaysia's facilitated registration pathway, they launched a one-year pilot
• 2:35
  Speaker 1: program on May 2nd, 2026. That's right. And the promise is...
• 2:40
  Speaker 1: is that eligible biosimilars, which are those highly complex therapeutic
• 2:45
  Speaker 1: products that mirror an existing biologic, can get a 60-working-day
• 2:49
  Speaker 1: registration timeline if they're already approved by the US FDA
• 2:53
  Speaker 1: or the European Medicines Agency.
• 2:55
  Speaker 2: Which is a full 30-day reduction from Malaysia's standard 90-day
• 2:58
  Speaker 2: abbreviated review. It's huge.
• 3:01
  Speaker 1: Think of this like a fast pass at a theme park.
• 3:02
  Speaker 2: Yeah.
• 3:03
  Speaker 1: So it lets you skip the massive winding main line,
• 3:05
  Speaker 1: but you still have to meet all the strict height requirements.
• 3:07
  Speaker 1: And the safety harness still has to click perfectly into
• 3:09
  Speaker 1: place before they actually let you on the ride.
• 3:12
  Speaker 2: I love that analogy. The underlying mechanism driving that fast
• 3:15
  Speaker 2: pass is what the industry calls a reliance pathway.
• 3:18
  Speaker 1: A reliance pathway.
• 3:19
  Speaker 2: Yeah. The NPRA is essentially acknowledging that highly trusted, stringent
• 3:25
  Speaker 2: regulatory authorities like the FDA or the EMA possess massive
• 3:29
  Speaker 2: resources and deep scientific expertise. Right.
• 3:33
  Speaker 1: They have huge teams.
• 3:34
  Speaker 2: Exactly. Exactly. So if those agencies have already done the
• 3:37
  Speaker 2: heavy lifting of a comprehensive scientific assessment, the NPRA feels
• 3:41
  Speaker 2: they don't need to reinvent the wheel by doing the
• 3:43
  Speaker 2: exact same math.
• 3:44
  Speaker 1: Makes sense.
• 3:45
  Speaker 2: They are relying on those prior assessments to reduce unnecessary
• 3:48
  Speaker 2: duplication of effort and clear their own administrative backlog.
• 3:53
  Speaker 1: But wait, if Malaysia is just, you know, reading the
• 3:54
  Speaker 1: SDA's homework, why does it even take 60 days? Well,
• 3:57
  Speaker 1: are they actually doing an independent review during that time?
• 4:00
  Speaker 1: Or is it basically just outsourcing the final Yes or
• 4:02
  Speaker 1: no decision?
• 4:03
  Speaker 2: No, reliance is fundamentally different from outsourcing. Malaysia firmly retains
• 4:07
  Speaker 2: the ultimate decision-making power and the sovereign regulatory responsibility for
• 4:12
  Speaker 2: their population. They are using the FDA or EMA's homework
• 4:15
  Speaker 2: to speed up their own evaluation process, but they are
• 4:18
  Speaker 2: still the teacher giving the final grade.
• 4:21
  Speaker 1: So they're still checking the work?
• 4:22
  Speaker 2: Rigorously. During their 60 days, the NPRA is verifying that
• 4:26
  Speaker 2: the product submitted to them is actually the same product
• 4:30
  Speaker 2: the FDA reviewed, and they are checking to ensure it
• 4:32
  Speaker 2: meets Malaysia's specific national health requirements.
• 4:35
  Speaker 1: And if it doesn't?
• 4:36
  Speaker 2: They can and will reject an application if it doesn't
• 4:40
  Speaker 2: align with their local standards.
• 4:42
  Speaker 1: That distinction brings us to the actual mechanics of this
• 4:45
  Speaker 1: 60-day clock. Because if this is a conditional fast pass...
• 4:50
  Speaker 1: The D.D. Riggs source material points out some major caveats
• 4:53
  Speaker 1: about how time is actually measured.
• 4:55
  Speaker 2: Oh, absolutely.
• 4:56
  Speaker 1: Submitting your paperwork on a Monday does not mean you
• 4:58
  Speaker 1: have an approval 60 working days later. The clock doesn't
• 5:01
  Speaker 1: even start when you hit submit.
• 5:02
  Speaker 2: Right. The administrative clock is highly conditional. The 60-day countdown
• 5:07
  Speaker 2: only begins after the application passes an initial screening phase.
• 5:11
  Speaker 1: You have to pay. Yes.
• 5:12
  Speaker 2: And the payment is officially confirmed. Everything prior to that
• 5:15
  Speaker 2: is basically just waiting to get into the starting blocks.
• 5:18
  Speaker 1: And the most concerning part for a sponsor is that
• 5:19
  Speaker 1: the clock completely stops while the agency is waiting for
• 5:22
  Speaker 1: the applicant to respond to any queries.
• 5:24
  Speaker 2: Yeah, that's a big one.
• 5:25
  Speaker 1: If the MPRA finds a discrepancy in the data and
• 5:29
  Speaker 1: sends a question to the developer, that 60-day timer just freezes.
• 5:33
  Speaker 1: The MPRA also strictly limits correspondence under this route to
• 5:37
  Speaker 1: a maximum of three rounds.
• 5:39
  Speaker 2: Exactly. When an agency stops the clock, the burden of
• 5:42
  Speaker 2: speed shifts entirely back to the sponsor. Right. Let's say
• 5:45
  Speaker 2: a developer forgets to include a specific manufacturing validation document.
• 5:50
  Speaker 2: The agency issues a query. The clock stops. If it
• 5:54
  Speaker 2: takes the developer three weeks to track down that document
• 5:57
  Speaker 2: and respond, those three weeks do not count against the
• 6:00
  Speaker 2: 60 days.
• 6:01
  Speaker 1: Wait, so that 60 days could easily stretch into months
• 6:04
  Speaker 1: in the real world.
• 6:04
  Speaker 2: Oh, easily. And those three rounds of correspondence are a
• 6:08
  Speaker 2: hard ceiling. You don't get endless opportunities to clarify confusing
• 6:11
  Speaker 2: data or fix formatting mistakes.
• 6:13
  Speaker 1: So a company could burn through their three lifelines just
• 6:16
  Speaker 1: fixing administrative sloppy work. And then if a real scientific
• 6:20
  Speaker 1: question comes up, they are out of chances.
• 6:22
  Speaker 2: That is the exact risk. Submitting an incomplete dossier or
• 6:26
  Speaker 2: going into the screening process with unresolved differences from your
• 6:29
  Speaker 2: FDA-approved product means you will likely exhaust your correspondence rounds. Wow.
• 6:34
  Speaker 2: If you hit that limit without resolving the agency's concerns,
• 6:37
  Speaker 2: your application can be outright rejected. Or you get kicked
• 6:41
  Speaker 2: out of the pilot pathway entirely and sent to the
• 6:44
  Speaker 2: back of the standard review queue. Ouch. A faster review
• 6:47
  Speaker 2: clock does not reduce the value of your upfront preparation.
• 6:51
  Speaker 2: It exponentially increases it. The speed is a reward for
• 6:55
  Speaker 2: regulatory alignment and having pristine documentation from day one.
• 6:59
  Speaker 1: To even qualify for that reward, a drug can't just
• 7:02
  Speaker 1: be any standard biosimilar. The eligibility requirements outlined in the
• 7:06
  Speaker 1: source are incredibly intense.
• 7:08
  Speaker 2: Intense.
• 7:09
  Speaker 1: First, the drug must have been approved by the FDA
• 7:11
  Speaker 1: or the EMA through what they call centralized procedures. Can
• 7:15
  Speaker 1: you give us, explain it like I'm five on what
• 7:17
  Speaker 1: a centralized procedure actually means in this context?
• 7:20
  Speaker 2: Sure. In regions like Europe, there are different ways to
• 7:23
  Speaker 2: get a drug approved. A company could apply for approval
• 7:26
  Speaker 2: in just one specific country like France or Germany. But
• 7:29
  Speaker 2: a centralized procedure means the European Medicines Agency evaluates the
• 7:33
  Speaker 2: drug on behalf of the entire European Union. It is
• 7:37
  Speaker 2: their most rigorous comprehensive pathway. Malaysia is specifying that they
• 7:41
  Speaker 2: will only rely on those highest tier region-wide assessments, not
• 7:46
  Speaker 2: on localized or conditional approvals where comprehensive data might still
• 7:50
  Speaker 2: be pending.
• 7:51
  Speaker 1: That filters out a lot of applications right away. Yeah.
• 7:54
  Speaker 1: But here is the most intense part of the eligibility criteria.
• 7:58
  Speaker 1: You have to submit your application to Malaysia's Quest system
• 8:02
  Speaker 1: within exactly three months of that reference agency approval.
• 8:06
  Speaker 2: Three months. It's a very tight window.
• 8:08
  Speaker 1: And the product you submit has to essentially be a
• 8:10
  Speaker 1: regulatory clone of the approved dossier.
• 8:12
  Speaker 2: What's fascinating here is how rigid that window is and
• 8:15
  Speaker 2: what it demands of the physical product itself.
• 8:18
  Speaker 1: Yeah.
• 8:18
  Speaker 2: To qualify for the 60-day route, the product submitted to
• 8:21
  Speaker 2: Malaysia must be effectively identical to the product approved by
• 8:25
  Speaker 2: the FDA or EMA. We are talking about the exact
• 8:28
  Speaker 2: same active ingredient, the same strength, the same dosage form,
• 8:31
  Speaker 2: and the same route of administration.
• 8:33
  Speaker 1: I mean, you'd expect the active ingredient to be the same. Otherwise,
• 8:36
  Speaker 1: it's a different drug entirely.
• 8:37
  Speaker 2: Right.
• 8:38
  Speaker 1: But the DD reg data shows the requirement goes much
• 8:40
  Speaker 1: deeper than that. The formulation composition has to be identical.
• 8:44
  Speaker 1: The container closure system, you know, the actual vial or
• 8:47
  Speaker 1: syringe holding the medicine must be identical with only very rare,
• 8:52
  Speaker 1: highly justified exceptions allowed.
• 8:55
  Speaker 2: And the most challenging hurdle for pharmaceutical supply chains is
• 8:59
  Speaker 2: that the manufacturing sites, the packaging sites, the testing sites,
• 9:02
  Speaker 2: and the batch release sites must all match the reference
• 9:06
  Speaker 2: agency's approval.
• 9:07
  Speaker 1: Wait, why does the packaging site matter so much? If
• 9:10
  Speaker 1: I make the drug in the U.S., but I want
• 9:12
  Speaker 1: to ship it in bulk to a packaging facility in
• 9:15
  Speaker 1: Singapore to save money on regional distribution in Asia... Why
• 9:19
  Speaker 1: would Malaysia reject that from the fast track?
• 9:22
  Speaker 2: Because the NPRA is relying on the FDA's inspection and verification.
• 9:26
  Speaker 2: If the FDA never inspected that specific packaging facility in Singapore,
• 9:30
  Speaker 2: they never signed off on its quality control or sterility standards.
• 9:33
  Speaker 1: That makes total sense.
• 9:34
  Speaker 2: Malaysia cannot rely on an FDA assessment for a facility
• 9:38
  Speaker 2: the FDA has never seen. So if your manufacturing or
• 9:41
  Speaker 2: packaging site differs from the reference dossier, Malaysia can no
• 9:45
  Speaker 2: longer use the reliance pathway.
• 9:47
  Speaker 1: It reminds me of trying to transfer credits between universities.
• 9:50
  Speaker 1: You take a heavy science course at your first college
• 9:53
  Speaker 1: and you try to transfer it to a new university.
• 9:55
  Speaker 2: Right.
• 9:55
  Speaker 1: If your old syllabus doesn't match the new school's expectations identically,
• 9:59
  Speaker 1: like write to the specific lab hours and textbook additions,
• 10:02
  Speaker 1: they won't accept the credit. They make you sit down
• 10:05
  Speaker 1: and retake the entire class from scratch.
• 10:08
  Speaker 2: That is the exact mechanism at play. If your dossier
• 10:11
  Speaker 2: isn't a clone, they make you retake the standard review process.
• 10:15
  Speaker 1: With all this reliance on the FDA and EMA... and
• 10:17
  Speaker 1: this demand for an identical clone dossier, does this mean
• 10:21
  Speaker 1: Malaysia is just, you know, wholesale adopting Western scientific standards
• 10:25
  Speaker 1: and abandoning their own?
• 10:26
  Speaker 2: Not at all.
• 10:27
  Speaker 1: Because when we look at the underlying science, the DD-RAG
• 10:31
  Speaker 1: insights make it clear that Malaysia's core requirements for demonstrating
• 10:34
  Speaker 1: biosimilarity haven't actually changed.
• 10:37
  Speaker 2: This raises an important question regarding what this pilot program
• 10:40
  Speaker 2: actually does. The 2026 route changes how the NPRA reviews
• 10:45
  Speaker 2: an eligible dossier administratively. It does not change the scientific
• 10:49
  Speaker 2: meaning of biosimilarity. Malaysia's second edition biosimilar guideline remains perfectly
• 10:55
  Speaker 2: aligned with the World Health Organization's 2022 guidelines. They still
• 10:59
  Speaker 2: demand a rigorous totality of evidence approach.
• 11:02
  Speaker 1: Let's define what that evidence looks like. Unlike small molecule
• 11:06
  Speaker 1: generic drugs like aspirin, which are just chemically synthesized and
• 11:11
  Speaker 1: relatively easy to copy exactly, Biologics are grown from living cells.
• 11:15
  Speaker 2: Right. They are incredibly complex, large molecules.
• 11:18
  Speaker 1: You can't just make a perfect generic copy of a biologic.
• 11:21
  Speaker 1: You make a biosimilar, which is highly similar but has
• 11:23
  Speaker 1: minor natural variations.
• 11:25
  Speaker 2: And proving that those minor natural variations don't affect how
• 11:28
  Speaker 2: the drug works requires extensive structural, physicochemical, biological, and functional characterization.
• 11:34
  Speaker 1: That's a lot of testing.
• 11:35
  Speaker 2: It is. Malaysia still expects developers to provide direct, head-to-head
• 11:39
  Speaker 2: comparability exercises against the original reference product. They want to
• 11:43
  Speaker 2: see comparative clinical evidence.
• 11:45
  Speaker 1: The source mentions pharmacokinetic and pharmacodynamic evaluations and immunogenicity assessments.
• 11:51
  Speaker 1: Let's break those down so we aren't drowning in jargon.
• 11:54
  Speaker 2: Good idea.
• 11:54
  Speaker 1: Pharmacokinetics is essentially what the body does to the drug, right?
• 11:58
  Speaker 1: Like how it absorbs it and breaks it down.
• 12:00
  Speaker 2: Correct. And pharmacodynamics is the reverse, what the drug does
• 12:04
  Speaker 2: to the body, how it binds to targets and creates
• 12:07
  Speaker 2: a therapeutic effect. Both of those have to match the
• 12:10
  Speaker 2: reference drug perfectly.
• 12:12
  Speaker 1: And immunogenicity is checking whether the patient's immune system will
• 12:16
  Speaker 1: accidentally treat this new biosimilar as an invader and attack it,
• 12:20
  Speaker 1: which could be incredibly dangerous.
• 12:22
  Speaker 2: Precisely. None of that scientific rigor disappears just because the
• 12:25
  Speaker 2: administrative review clock is shorter. The MPRA is still checking
• 12:29
  Speaker 2: every piece of that clinical puzzle.
• 12:31
  Speaker 1: And on top of that clinical puzzle, there are strictly
• 12:33
  Speaker 1: local requirements that developers have to bolt onto this clone dossier.
• 12:37
  Speaker 1: The FDA does its stability testing in places like Maryland,
• 12:40
  Speaker 1: where the climate is pretty temperate.
• 12:42
  Speaker 2: Right.
• 12:43
  Speaker 1: But Malaysia is a tropical country.
• 12:44
  Speaker 2: Right.
• 12:45
  Speaker 1: I'm assuming that is why the NPRA strictly requires Asian
• 12:49
  Speaker 1: zone IV stability data.
• 12:50
  Speaker 2: The environment matters deeply for biologics. They are very sensitive
• 12:54
  Speaker 2: to temperature and moisture. Zone IVB is the climate classification
• 12:59
  Speaker 2: for very hot and very humid environments.
• 13:01
  Speaker 1: Got it.
• 13:02
  Speaker 2: To get approved in Malaysia, sponsors must include at least
• 13:04
  Speaker 2: 12 months of real-time stability data. and six months of
• 13:08
  Speaker 2: accelerated stability data, specifically testing the drug under those intense
• 13:13
  Speaker 2: zone IVB conditions.
• 13:14
  Speaker 1: So even if your core clinical data is a perfect
• 13:17
  Speaker 1: FDA clone, if you haven't been running parallel stability tests
• 13:21
  Speaker 1: in high humidity chambers for the last year, you can't submit.
• 13:24
  Speaker 2: Exactly.
• 13:25
  Speaker 1: You also have to provide a specific pharmacovigilance risk management plan,
• 13:29
  Speaker 1: or RMP, that addresses safety considerations unique to the Malaysian
• 13:33
  Speaker 1: healthcare system, along with translating and formatting local Malaysian labeling.
• 13:37
  Speaker 2: You are basically taking a globally standardized clinical foundation and
• 13:41
  Speaker 2: wrapping it in highly localized safety and stability metrics.
• 13:45
  Speaker 1: Here's where it gets really interesting. When you zoom out,
• 13:47
  Speaker 1: you realize that health authorities worldwide are wrestling with this
• 13:51
  Speaker 1: exact same problem.
• 13:52
  Speaker 2: Oh, absolutely.
• 13:53
  Speaker 1: How do you balance the desperate need to get life-saving,
• 13:56
  Speaker 1: cost-saving biosimilars to patients quickly with the absolute necessity of
• 14:01
  Speaker 1: rigorous local oversight? How does Malaysia's 2026 update fit into
• 14:06
  Speaker 1: the broader global landscape because they aren't the only ones
• 14:09
  Speaker 1: doing this.
• 14:10
  Speaker 2: Every region is handling this balance differently, largely based on
• 14:14
  Speaker 2: their internal resources and their regulatory philosophies. Take Singapore's Health
• 14:18
  Speaker 2: Sciences Authority, the HSO, for instance. They have been very
• 14:22
  Speaker 2: proactive in regional reliance. They explicitly use what they call
• 14:26
  Speaker 2: abridged and verification evaluation routes.
• 14:29
  Speaker 1: How do those differ from what Malaysia is doing?
• 14:31
  Speaker 2: Well, Singapore's abridged review can rely on an approval from
• 14:35
  Speaker 2: just one recognized reference agency. Their verification route is even faster.
• 14:39
  Speaker 2: That applies to drugs where at least two reference agencies
• 14:42
  Speaker 2: have approved a suitably aligned product.
• 14:44
  Speaker 1: Wow, that is fast.
• 14:45
  Speaker 2: Singapore has a smaller population and a highly efficient, pragmatic
• 14:49
  Speaker 2: regulatory culture. They are comfortable leaning heavily on trusted global
• 14:52
  Speaker 2: partners to ensure fast access for their citizens.
• 14:55
  Speaker 1: But then you look at the major players, the EU
• 14:58
  Speaker 1: and the U.S. FDA. They take a completely different approach.
• 15:01
  Speaker 1: They do not rely on anyone else's prior foreign approvals
• 15:05
  Speaker 1: to make their decisions. No, they don't.
• 15:06
  Speaker 2: The EMA in Europe and the FDA in the U.S.
• 15:09
  Speaker 2: have the massive funding, the deep benches of scientific personnel,
• 15:12
  Speaker 2: and the legislative mandates to set global standards. They perform
• 15:16
  Speaker 2: their own dedicated scientific assessments from the ground up. The
• 15:20
  Speaker 2: FDA uses an abbreviated statutory pathway for biosimilars, But they
• 15:24
  Speaker 2: rely on their own exhaustive assessment to ensure there are
• 15:27
  Speaker 2: no clinically meaningful differences from a reference product.
• 15:31
  Speaker 1: They are the agencies generating the homework that the rest
• 15:33
  Speaker 1: of the world relies on.
• 15:34
  Speaker 2: Exactly.
• 15:35
  Speaker 1: Japan's Pharmaceuticals and Medical Devices Agency, the PMDA, is another
• 15:39
  Speaker 1: fascinating example. They also conduct their own science-based assessments.
• 15:43
  Speaker 2: They do.
• 15:43
  Speaker 1: The DDREG source noted that throughout 2026, Japan has been
• 15:47
  Speaker 1: continuously refining its approach, specifically issuing new considerations in Q
• 15:52
  Speaker 1: & A material on when comparative efficacy studies are necessary.
• 15:56
  Speaker 1: Why is Japan so focused on comparative efficacy?
• 15:59
  Speaker 2: Well, comparative efficacy studies are massive clinical trials to prove
• 16:03
  Speaker 2: the biosimilar treats the disease exactly as well as the
• 16:07
  Speaker 2: original drug.
• 16:08
  Speaker 1: Okay.
• 16:08
  Speaker 2: In the global regulatory community, there is a fierce debate
• 16:12
  Speaker 2: about whether these massive trials are always necessary if the
• 16:15
  Speaker 2: structural biology perfectly matches. Right. But Japan often requires specific
• 16:20
  Speaker 2: clinical data to prove that the drug works identically in
• 16:23
  Speaker 2: Japanese populations, accounting for potential genetic or metabolic differences. They
• 16:28
  Speaker 2: are refining their guidelines to clarify exactly when a developer
• 16:32
  Speaker 2: can skip those massive trials and when they are absolutely
• 16:35
  Speaker 2: mandatory for the Japanese market.
• 16:37
  Speaker 1: Tying this massive global web together is the World Health Organization.
• 16:42
  Speaker 1: The WHO provides the baseline standards for everyone. They are
• 16:45
  Speaker 1: actively promoting both scientifically robust biosimilar evaluation and what they
• 16:50
  Speaker 1: call good reliance practices.
• 16:52
  Speaker 2: The WHO sees reliance not as a sign of weakness
• 16:55
  Speaker 2: or a lack of sovereign capability, but as a vital
• 16:58
  Speaker 2: tool for global health equity.
• 17:00
  Speaker 1: That's a great point.
• 17:01
  Speaker 2: There is a limited amount of regulatory scientific expertise in
• 17:05
  Speaker 2: the world. Having 60 different countries do the exact same
• 17:10
  Speaker 2: math on the exact same biologic drug is is a
• 17:13
  Speaker 2: massive waste of global resources.
• 17:15
  Speaker 1: It really is.
• 17:16
  Speaker 2: Reliance allows smaller or more resource-constrained nations to clear their
• 17:21
  Speaker 2: backlogs and get medicines to their populations years faster.
• 17:25
  Speaker 1: Knowing this global context and knowing the strict local rules
• 17:29
  Speaker 1: like that ocean zone IV stability data, how does a
• 17:33
  Speaker 1: pharmaceutical team actually execute a launch without blowing themselves up?
• 17:37
  Speaker 2: It's a huge challenge.
• 17:38
  Speaker 1: If I am a regulatory strategy leader, this 60-day prize
• 17:41
  Speaker 1: sounds amazing, But the operational minefield to get there sounds terrifying.
• 17:46
  Speaker 2: It fundamentally forces companies to change their launch sequencing. Historically,
• 17:50
  Speaker 2: a pharmaceutical company used a regulatory wave strategy.
• 17:53
  Speaker 1: Like doing it in phases.
• 17:54
  Speaker 2: Right. They would focus all their money and energy on
• 17:57
  Speaker 2: securing the US FDA or European EMA approval first. Once
• 18:01
  Speaker 2: that was secured, they would take a breath, start collecting revenue,
• 18:04
  Speaker 2: and then maybe a year later, they would start assembling
• 18:06
  Speaker 2: a customized dossier for Southeast Asia. Markets like Malaysia were
• 18:09
  Speaker 2: typically treated as a wave two or wave three launch.
• 18:13
  Speaker 1: But because of that strict three-month submission window in Malaysia's
• 18:16
  Speaker 1: new pathway, you can't do that sequential wave anymore.
• 18:20
  Speaker 2: No, you can't.
• 18:20
  Speaker 1: If you wait until the FDA gives you the green
• 18:22
  Speaker 1: light to even start translating documents for Malaysia, you will
• 18:27
  Speaker 1: miss the three-month deadline entirely.
• 18:29
  Speaker 2: The three-month countdown from the reference agency's approval date is
• 18:32
  Speaker 2: completely unforgiving. As we discussed... Submitting a half-finished dossier just
• 18:38
  Speaker 2: to stop the clock doesn't work. An incomplete application at
• 18:41
  Speaker 2: the screening phase will be rejected and doesn't establish a
• 18:44
  Speaker 2: valid submission date. You have to be ready to hit
• 18:47
  Speaker 2: submit in Malaysia's system almost the exact moment the FDA
• 18:51
  Speaker 2: pops the champagne.
• 18:52
  Speaker 1: That means developers must prepare in parallel. While the FDA
• 18:55
  Speaker 1: is doing their final nine-month reviews, the regulatory team has
• 18:59
  Speaker 1: to be simultaneously finalizing the Malaysian sameness assessment, wrapping up
• 19:03
  Speaker 1: the 12-month ACN stability data, and formatting the local risk
• 19:07
  Speaker 1: management plans.
• 19:09
  Speaker 2: Parallel processing is the only way to succeed under this pilot.
• 19:12
  Speaker 2: You have to map the expected FDA or EMA approval
• 19:15
  Speaker 2: against every single NPRA criterion a year in advance. But
• 19:20
  Speaker 2: if we connect this to the bigger picture, the strategic
• 19:23
  Speaker 2: payoff for doing that parallel work is massive. Earning that
• 19:27
  Speaker 2: 60-day NPRA registration means an incredibly early commercial access strategy
• 19:32
  Speaker 2: in Southeast Asia. Right. It elevates Malaysia from an afterthought
• 19:36
  Speaker 2: to a primary wave one launch target, which transforms the
• 19:40
  Speaker 2: revenue curve for the drug.
• 19:42
  Speaker 1: But the pitfalls are everywhere. DGREG highlighted some common operational
• 19:46
  Speaker 1: mistakes that completely ruin a developer's eligibility. The first is
• 19:50
  Speaker 1: a pure assumption error, assuming that any FDA-approved biosimilar automatically
• 19:55
  Speaker 1: qualifies for Malaysia's fast track.
• 19:57
  Speaker 2: Right, which we know isn't true.
• 19:59
  Speaker 1: As we covered with the centralized procedure requirement, they don't.
• 20:02
  Speaker 2: Another fatal mistake is tinkering with the supply chain before
• 20:05
  Speaker 2: the Malaysian submission.
• 20:06
  Speaker 1: Like changing where it's made.
• 20:07
  Speaker 2: Exactly. A company might get FDA approval using a high-cost
• 20:11
  Speaker 2: manufacturing facility in the U.S. To supply the Asian market,
• 20:15
  Speaker 2: they try to shift production to a newer, cheaper facility
• 20:18
  Speaker 2: in the region, thinking it's the same formula, so it
• 20:20
  Speaker 2: shouldn't matter.
• 20:21
  Speaker 1: But it does matter.
• 20:22
  Speaker 2: Under this reliance pilot, it matters entirely. The facilities must
• 20:26
  Speaker 2: be identical. If you change the site, you lose the
• 20:28
  Speaker 2: reliance pathway.
• 20:29
  Speaker 1: Another massive unforced error is treating the Asian stability requirements
• 20:34
  Speaker 1: as a post-submission issue. A developer might think, you know,
• 20:38
  Speaker 1: we'll just submit the core clinical data now to hit
• 20:40
  Speaker 1: the three-month window, and we'll send them the humidity data
• 20:43
  Speaker 1: later when they ask for it.
• 20:44
  Speaker 2: If you do that, your dossier is deemed incomplete during
• 20:47
  Speaker 2: the initial screening. The clock never starts. You lose your
• 20:50
  Speaker 2: submission date, you blow past the three-month window, and your
• 20:54
  Speaker 2: multi-million dollar strategy is suddenly back in the standard review queue.
• 20:58
  Speaker 1: That is brutal.
• 20:59
  Speaker 2: Furthermore, sponsors have to secure the actual assessment reports from
• 21:02
  Speaker 2: the FDA or EMA before they submit to Malaysia. You
• 21:06
  Speaker 2: cannot treat securing those reference documents as an administrative chore
• 21:09
  Speaker 2: to handle later.
• 21:11
  Speaker 1: So what does this all mean? If we synthesize everything
• 21:14
  Speaker 1: we've pulled from the DD Reg Insights today, Malaysia's 2026
• 21:17
  Speaker 1: NPRA pilot is a remarkably powerful tool for accelerating biosimilar
• 21:23
  Speaker 1: registration and getting critical medicines to patients faster.
• 21:26
  Speaker 2: It really is.
• 21:27
  Speaker 1: Cutting a review time down to 60 working days is
• 21:30
  Speaker 1: a huge leap forward for global health coordination. But it
• 21:33
  Speaker 1: is a precision tool strictly reserved for developers who can
• 21:36
  Speaker 1: maintain absolute cloned dossier sameness.
• 21:39
  Speaker 2: Right.
• 21:40
  Speaker 1: Who understand the scientific necessity of local requirements like zone
• 21:43
  Speaker 1: IV stability, and who can orchestrate a global launch in
• 21:46
  Speaker 1: parallel to hit a very narrow three-month window.
• 21:49
  Speaker 2: The overarching lesson for the pharmaceutical industry is that regulatory
• 21:53
  Speaker 2: speed is never truly free. It is earned. Yeah. It
• 21:56
  Speaker 2: is earned through meticulous, proactive, upfront alignment across multiple continents simultaneously.
• 22:02
  Speaker 2: You cannot buy your way into a fast pass lane.
• 22:04
  Speaker 2: You have to engineer your entire regulatory strategy to perfectly
• 22:08
  Speaker 2: match the dimensions of the fast track.
• 22:10
  Speaker 1: And that leaves us with a final thought for you
• 22:11
  Speaker 1: to mull over. As we see more countries like Malaysia
• 22:15
  Speaker 1: and Singapore adopting these highly sophisticated reliance pathways to clear
• 22:19
  Speaker 1: administrative backlogs and speed up access to complex biologics, are
• 22:24
  Speaker 1: we slowly, quietly inching toward a de facto global passport
• 22:29
  Speaker 1: for medicines?
• 22:30
  Speaker 2: That's an interesting question.
• 22:31
  Speaker 1: Are we moving toward a future where one rigorous approval
• 22:34
  Speaker 1: truly opens doors everywhere? Or will the stubborn physical realities
• 22:38
  Speaker 1: of regional specifics, you know, the intense tropical humidity zones,
• 22:42
  Speaker 1: the differing local clinical practices, and the genetic variations in
• 22:46
  Speaker 1: global populations always keep true frictionless global harmonization just out
• 22:50
  Speaker 1: of reach? Will a pharmaceutical developer ever truly be able
• 22:53
  Speaker 1: to skip the line entirely? Or will there always be
• 22:56
  Speaker 1: another critical local safety check waiting at the border?